as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹2,236.7
Change
-19.5 (-0.86%)
Open
₹2,273.0
Prev. Close
₹2,256.2
Day High
₹2,278.2
Day Low
₹2,220.0
Volume Analysis
Traded
25,615
Delivered
13,881
Delivery %
54.19%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (29.5%)
- •Strong operating margin (21.0%)
Weaknesses (0)
No signal for this stock
Opportunities (3)
- •Strong 3-year EPS growth (29.7%)
- •Strong 3-year revenue growth (16.7%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹2,328.14 | ₹2,303.17 | ₹2,269.94 | ₹2,244.97 | ₹2,211.74 | ₹2,186.77 | ₹2,153.54 |
| Fibonacci | ₹2,303.17 | ₹2,280.94 | ₹2,267.2 | ₹2,244.97 | ₹2,222.74 | ₹2,209.0 | ₹2,186.77 |
| Camarilla | ₹2,252.71 | ₹2,247.37 | ₹2,242.04 | ₹2,244.97 | ₹2,231.37 | ₹2,226.03 | ₹2,220.7 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+59.49%
1 Week
-4.5%
1 Month
+10.68%
3 Months
+4.39%
6 Months
+32.77%
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
25.55%
Net margin 13.28% × asset turnover 1.21x × equity multiplier 1.59x
Company Overview
Sector
Healthcare
Market Cap
₹14,010 Cr
P/E (TTM)
63.6
ROE
29.5%
Book Value
₹132.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.
TopFund Analysis
Corona Remedies Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 74/100. The strongest factor is Financial Strength (100/100), while Valuation (2/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (29.5%); strong operating margin (21.0%). Strong 3-year EPS growth (29.7%).
TopFund Score — Fundamentals Quality
74/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has a good return on equity (ROE) track record: 3 Years ROE 26.5%
- +Company has been maintaining a healthy dividend payout of 29.3%
- −Stock is trading at 17.4 times its book value
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Transcript of Earnings Call with Analyst / Investor on Unaudited Financial Results for the second quarter and half year ended September 30, 2026
NPPA issued demand notice of ₹4.88 crore on November 3, 2026 for alleged DPCO 2013 violation.
Audio recording of Q2/H1 FY27 earnings conference call is available on company website.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 314 | 298 | 294 | 347 | 361 | 342 | 353 | 422 | 441 |
| Expenses + | 247 | 228 | 239 | 277 | 283 | 259 | 291 | 329 | 345 |
| Operating Profit | 67 | 69 | 54 | 70 | 78 | 83 | 62 | 93 | 96 |
| OPM % | 21.0% | 23.0% | 18.0% | 20.0% | 22.0% | 24.0% | 18.0% | 22.0% | 22.0% |
| Other Income + | 2 | 1 | 2 | 2 | 2 | -17 | 4 | 3 | 3 |
| Interest | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 3 | 3 |
| Depreciation | 9 | 10 | 10 | 9 | 9 | 9 | 10 | 13 | 15 |
| Profit before tax | 57 | 58 | 44 | 61 | 70 | 55 | 55 | 80 | 81 |
| Tax % | 25.0% | 23.0% | 28.0% | 24.0% | 25.0% | 25.0% | 17.0% | 25.0% | 25.0% |
| Net Profit + | 43 | 45 | 32 | 46 | 52 | 41 | 45 | 60 | 60 |
| EPS in Rs | 7 | 7 | 5 | 8 | 9 | 7 | 7 | 10 | 10 |
| Raw PDF | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | 15 | 15 | 20 | 22 | 22 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 509 | 601 | 576 | 617 | 884 | 1,014 | 1,196 | 1,403 | 1,559 |
| Expenses + | 444 | 509 | 471 | 600 | 756 | 859 | 956 | 1,109 | 1,225 |
| Operating Profit | 66 | 93 | 105 | 18 | 128 | 156 | 241 | 294 | 334 |
| OPM % | 13.0% | 15.0% | 18.0% | 2.9% | 14.0% | 15.0% | 20.0% | 21.0% | 21.0% |
| Other Income + | 3 | 3 | 5 | 7 | 7 | 5 | 6 | -9 | -7 |
| Interest | 1 | 2 | 2 | 5 | 4 | 14 | 11 | 7 | 8 |
| Depreciation | 14 | 16 | 16 | 20 | 20 | 28 | 37 | 38 | 48 |
| Profit before tax | 54 | 77 | 92 | -1 | 111 | 118 | 199 | 240 | 271 |
| Tax % | 35.0% | 24.0% | 24.0% | -49.0% | 23.0% | 24.0% | 25.0% | 23.0% | — |
| Net Profit + | 35 | 59 | 70 | 0 | 85 | 90 | 149 | 185 | 207 |
| EPS in Rs | 7 | 12 | 14 | 0 | 14 | 15 | 24 | 30 | 34 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 20.0% | 25.0% | 30.0% | 33.0% | — |
| Sales growth | — | 18 | -4 | 7 | — | 15 | 18 | 17 | 20 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Reserves | 204 | 263 | 333 | 270 | 347 | 419 | 545 | 686 | 744 |
| Borrowings + | 13 | 47 | 50 | 34 | 28 | 159 | 86 | 165 | 115 |
| Other Liabilities + | 71 | 94 | 144 | 157 | 159 | 191 | 237 | 293 | 326 |
| Total Liabilities | 293 | 408 | 532 | 511 | 595 | 831 | 930 | 1,205 | 1,247 |
| Fixed Assets + | 80 | 81 | 164 | 162 | 185 | 384 | 370 | 554 | 698 |
| CWIP | 4 | 42 | 0 | 14 | 65 | 121 | 186 | 143 | 22 |
| Investments | 9 | 7 | 37 | 14 | 32 | 26 | 26 | 26 | 0 |
| Other Assets + | 200 | 278 | 330 | 321 | 314 | 301 | 348 | 482 | 526 |
| Total Assets | 293 | 408 | 532 | 511 | 595 | 831 | 930 | 1,205 | 1,247 |
| Equity Capital | 5 | 5 | 5 | 51 | 61 | 61 | 61 | 61 | 61 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 19 | 43 | 79 | 98 | 103 | 157 | 190 | 229 |
| Cash from Investing Activity + | -23 | -50 | -102 | -66 | -50 | -267 | -84 | -256 |
| Cash from Financing Activity + | 4 | 30 | 0 | -30 | -45 | 99 | -107 | 25 |
| Net Cash Flow | -1 | 23 | -23 | 2 | 8 | -11 | 0 | -1 |
| Free Cash Flow | 19 | 1 | 6 | 64 | 9 | -129 | 99 | 56 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 49 | 65 | 101 | 557 | 100 | 112 | 97 | 95 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|
| Public | 22.41% | 21.75% | 14.47% | 10.35% |
| Promoters | 69.0% | 69.0% | 69.0% | 69.0% |
| FII | 1.84% | 2.25% | 3.63% | 4.21% |
| DII | 6.77% | 7.02% | 12.9% | 16.44% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Corona Remedies Limited (this stock) | 14,010 | 63.6 | 17.34 | 29.5% |
| Sudeep Pharma Limited | 13,545 | 71.9 | 14.14 | 25.2% |
| Vijaya Diagnostic Cen Ltd | 14,524 | 71.3 | 13.69 | 18.9% |
| Marksans Pharma Limited | 13,347 | 23.8 | 4.0 | 15.2% |
| Jubilant Pharmova Ltd | 14,883 | 50.4 | 2.08 | 6.53% |
| Rainbow Childrens Med Ltd | 12,607 | 43.0 | 7.34 | 16.7% |
| Indegene Limited | 15,640 | 36.7 | 4.67 | 14.4% |
Which Mutual Funds Hold Corona Remedies Limited?
Frequently Asked Questions about Corona Remedies Limited
Corona Remedies Limited (CORONA) closed at ₹2,236.7 on NSE on 19 November 2026, down 19.5 (0.86%) from the previous close.
Corona Remedies Limited trades on the NSE (National Stock Exchange of India) under the symbol CORONA.
Corona Remedies Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 63.6.
Corona Remedies Limited has a dividend yield of 0.44%.
Corona Remedies Limited's 52-week high is ₹2,719.0 and its 52-week low is ₹1,337.0.
Corona Remedies Limited has a market capitalisation of ₹14,010 crore.
Corona Remedies Limited has a TopFund Quality Score of 74/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Corona Remedies Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.